Decreased Sputum Type-2 Gene Expression in COPD Current Smokers

Area of Science:

• Pulmonary Medicine
• Immunology
• Respiratory Research

Background:

• Higher blood eosinophil counts in COPD patients correlate with better inhaled corticosteroid (ICS) response.
• Type 2 (T2) inflammation is a key target for ICS in COPD management.
• Current smokers exhibit diminished responses to ICS treatment.

Purpose of the Study:

• To investigate if current smoking influences airway T2 mediator levels.
• To determine the impact of smoking status on T2 inflammation in COPD.
• To understand how smoking affects ICS responsiveness in COPD patients.

Main Methods:

• Collected induced sputum samples from 73 COPD patients (current smokers and ex-smokers).
• Assessed sputum gene expression of IL13, CLCA1, CCL26, and CST1 using quantitative RT-PCR.
• Performed differential cell counts and analyzed gene expression stability over time.

Main Results:

• All four genes correlated with sputum eosinophil percentages.
• COPD current smokers showed significantly lower IL13 and CCL26 gene expression compared to ex-smokers.
• IL13, CCL26, and CST1 gene expression demonstrated good consistency in repeat samples.

Conclusions:

• Sputum IL13 and CCL26 gene expression are influenced by smoking status in COPD patients.
• Current smoking appears to shift the immune response away from a T2 inflammatory profile in COPD.
• IL-13 and CCL26 are implicated as crucial components of T2 inflammation in COPD.